Dragonfly and Celgene Extended their Collaboration from 2017, for the Treatment of Solid and Hematological Cancers

 Dragonfly and Celgene Extended their Collaboration from 2017, for the Treatment of Solid and Hematological Cancers

Dragonfly and Celgene Extended their Collaboration from 2017, for the Treatment of Solid and Hematological Cancers

Shots:

  • Celgene has added four more immunotherapies (making it eight, to 2017 deal) to develop and commercialize with an option to license WW IPR of the developed product, using Dragonfly’s TriNKET technology
  • Dragonfly to get $50M upfront with milestones and royalties (if the option to license is exercised by Celgene)
  • TriNKET technology (Tri-specific, NK cell Engager Therapeutics) uses NK cells, for developing immunotherapies for cancer

Click here to read full press release/ article | Ref: PRNewsWire| Image:  The Street

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post